The following information is obtained from various newswires,
published medical journal articles, and medical conference presentations.
Company: Knoll Pharmaceutical
Approval Status: Approved January 1998
Treatment for: Paroxysmal atrial fibrillation
General Information
Rymol (propafenone hydrochloride) has been approved for use in patients without structural heart disease, for prolongation of the time to recurrence of paroxysmal atrial fibrillation/flutter and paroxysmal supraventricular tachycardia associated with disabling symptoms. The drug has been marketed in the U.S. since 1990 for patients with life-threatening ventricular arrhythmias.
Clinical Results
In a 12-month study, patients' time to recurrence of paroxysmal atrial fibrillation/flutter, or sudden arrhythmic attacks, was eight times longer in patients receiving Rythmol versus patients treated with placebo.
